Computing competing risks based on family history in genetic diseases with variable age at onset

Alexandra Lefebvre, Olivier Bouaziz, Grégory Nuel Curie Institut - LPMA, UPMC - University Paris 11, France

> SAM 2017 University of Liverpool








A. Lefebvre 1 / 13

Introduction: Context

- The breast cancer
 - 1st cancer in women. 55,000 women in the UK each year
 - Complex disease due to an accumulation of mutations
 (ie.: BRCA 1/2 and/or PALB2 and/or RAD51 and/or, etc.)
 - 10 to 15% cases: inherited mutation.
- The genetic counseling



 $\begin{array}{c} \text{Genetic testing} \\ \mathbb{P}(\text{genetic predisposition} \,|\, FH) \\ \text{Individual risk of the disease} \,|\, FH \end{array} \right\} \rightarrow \text{recommendations}$


A. Lefebvre 2 / 13

Introduction: existing models

- Empirical : The GAIL model (logistic regression)
- Mendelian : Claus-Easton, BRCAPro, BOADICEA, etc.

The Claus-Easton model [Claus et al., 1991, Easton et al., 1993]

- Autosomal, biallelic, dominant, estimated allele frequency f=0.33%
- The hazard functions per genotype (piecewise constant) :



Objectives : Impl. sum/product algorithm + competing risk of death

A. Lefebvre

The model: the likelihood and the genotypes

$$\mathbb{P}(X, \mathrm{FH}) = \prod_{i} \mathbb{P}(X_{i} | X_{\mathsf{pat}_{i}}, X_{\mathsf{mat}_{i}}) \times \prod_{i} \mathbb{P}(\mathrm{PH}_{i} | X_{i}), \quad \mathrm{FH} = \{\mathrm{PH}_{i}\}_{i}$$
genotypes

phenotypes

Mode of inheritance: 1 autosomal biallelic gene, f = 0.33%

Founders (Hardy-Weinberg) :
$$\begin{cases} \mathbb{P}(X_i = 00) = (1 - f)^2 \\ \mathbb{P}(X_i = 10) = \mathbb{P}(X_i = 01) = f(1 - f) \\ \mathbb{P}(X_i = 11) = f^2 \end{cases}$$

$$\text{Offsprings (Mendel): } \left\{ \begin{array}{l} \mathbb{P}(X_i = 00) = (1 - \Theta(X_{\mathsf{pat}})) \times (1 - \Theta(X_{\mathsf{mat}})) \\ \mathbb{P}(X_i = 10) = \Theta(X_{\mathsf{pat}}) \times (1 - \Theta(X_{\mathsf{mat}})) \\ \mathbb{P}(X_i = 01) = (1 - \Theta(X_{\mathsf{pat}})) \times \Theta(X_{\mathsf{mat}}) \\ \mathbb{P}(X_i = 11) = \Theta(X_{\mathsf{pat}}) \times \Theta(X_{\mathsf{mat}}) \end{array} \right.$$

with
$$\Theta(00) = 0$$
, $\Theta(10) = \Theta(01) = 0.5$, $\Theta(11) = 1$

A. Lefebvre 4 / 13

The model: the phenotypes

With T_i , the age at disease onset for individual iSurvival data : $PH_i = \left\{ \begin{array}{l} \{T_i > \tau_i\} & \text{if } i \text{ is censored at age } \tau_i \\ \{T_i = \tau_i\} & \text{if } i \text{ is affected at age } \tau_i \end{array} \right.$

Dominant model of disease:

$$\lambda(t|X_i) = \begin{cases} \lambda_0(t) & \text{if } X = 00 \\ \lambda_1(t) & \text{if } X \neq 00 \text{ i.e. } \in \{10, 01, 11\} \end{cases}$$


- For a censored individual at age τ_i $\mathbb{P}(\mathrm{PH}_i|X_i) = \mathbb{P}(T_i > \tau_i|X_i) = \begin{cases} S_0(\tau_i) & \text{for non-carriers} \\ S_1(\tau_i) & \text{for carriers} \end{cases}$
- For an affected individual at age τ_i $\mathbb{P}(\mathrm{PH}_i|X_i) = \mathbb{P}(T_i = \tau_i|X_i) = \left\{ \begin{array}{l} S_0(\tau_i)\lambda_0(\tau_i) & \text{for non-carriers} \\ S_1(\tau_i)\lambda_1(\tau_i) & \text{for carriers} \end{array} \right.$

A. Lefebvre 5 / 13

Model: The bayesian network¹; sum-product algorithm

$$\mathbb{P}(X, \operatorname{FH}) = \prod_{i} \underbrace{\mathbb{P}(X_{i}|X_{\mathsf{pat}_{i}}, X_{\mathsf{mat}_{i}})\mathbb{P}(\operatorname{FH}_{i}|X_{i})}_{\mathrm{K}_{i}(X_{i}|X_{\mathsf{pat}_{i}}, X_{\mathsf{mat}_{i}})} \to \mathbb{P}(\operatorname{FH}) = \sum_{X} \prod_{i} \mathrm{K}_{i}(X_{i}|X_{\mathsf{pat}_{i}}, X_{\mathsf{mat}_{i}})$$


With $X \in \{00, 10, 01, 11\}^n \rightarrow 4^n$ configurations



¹[Koller and Friedman, 2009]

A. Lefebvre 6 / 13

Belief propagation



Bayesian network

Complexity $\mathcal{O}(4^n) \to \mathcal{O}(n \times 4^k)$, k:tree-width (ex: k=3 if no loop) F & B computed once for any later marginal or joint distribution needed

A. Lefebvre 7 / 13

Model: Disease risk prediction for an unaffected individual


$$\pi(\tau) = \mathbb{P}(\mathsf{carrier}|\mathsf{FH})$$

• Breast cancer specific, no competing risk $\frac{S(t|\text{FH})}{S(t|\text{FH})} = \sum_{X_i} \mathbb{P}(T > t, X_i|\text{FH}) = \pi(\tau) \frac{S_1(t)}{S_1(\tau)} + (1 - \pi(\tau)) \frac{S_0(t)}{S_0(\tau)}$ $\pi(t|\text{FH}) = \frac{\pi(\tau)S_1(t)}{S(t|\text{FH})S_1(\tau)}$ $\lambda_{disease}(t|\text{FH}) = \pi(t|\text{FH})\lambda_1(t) + (1 - \pi(t|\text{FH}))\lambda_0(t)$

• With competing risk of death : $T^* = \min(T_{\text{disease}}, T_{\text{death}})$ $\lambda_{\text{both}}(t|\text{FH}) = \lambda_{\textit{disease}}(t|\text{FH}) + \lambda_{\text{death}}(t)$: hazard function of T^* $\mathbb{P}(T \le t|\text{FH}) = \int_{\tau}^{t} S_{\text{both}}(u)\lambda_{\text{disease}}(u)du$ $= \int_{\tau}^{t} \exp\left(-\int_{\tau}^{u} \lambda_{\text{both}}(v)dv\right)\lambda_{\text{disease}}(u)du$ \rightarrow discretized $\lambda \rightarrow$ closed form formulas for pch


A. Lefebvre 8 / 13

Results: Carrier risk, posterior marginal carrier distribution




A. Lefebvre 9 / 1:

Results: Carrier risk, posterior marginal carrier distribution




A. Lefebvre 10 / 13

Results, Disease risk, With competing death




A. Lefebvre

Results, Disease risk, With competing death



Ind. risk with vs without competing risk of death



Difference in % of S(100) with vs without competing risk

A. Lefebvre 11 / 13

Conclusion

- The model
 - Adaptable (any genetic disease and model of disease)
 - Fast (bayesian network sum-product algorithm belief propagation)
 - Takes into account the competing risk of death

- What's next?
 - Parameters estimations
 - Complex distributions (number of carriers in the family) with generating functions of probabilities (polynomials) \rightarrow familial risk

• Multi-state and frailty models

A. Lefebvre 12 / 13

Claus, E. B., Risch, N., and Thompson, W. D. (1991).
Genetic analysis of breast cancer in the cancer and steroid hormone study.

American journal of human genetics, 48(2):232.

Easton, D., Bishop, D., Ford, D., and Crockford, G. (1993).

Genetic linkage analysis in familial breast and ovarian cancer: results

American journal of human genetics, 52(4):678.

Koller, D. and Friedman, N. (2009). *Probabilistic graphical models: principles and techniques.* MIT press.

from 214 families. the breast cancer linkage consortium.

A. Lefebvre 13 / 13

Thank you for your attention



A. Lefebvre